Director Michael Holder of Cytek Biosciences, Inc. filed a Form 4 on November 20, 2026, disclosing the vesting and conversion of 2,181 restricted stock units into common stock on November 18, 2026.
Key Highlights
- Reporting person: Michael Holder, Director of Cytek Biosciences, Inc. (NASDAQ:CTKB)
- Transaction date: November 18, 2026, with transaction code M (conversion of derivative security)
- Shares acquired: 2,181 shares of common stock acquired via RSU vesting, at a derivative price of $0
- Post-transaction common stock ownership: 65,056 shares held directly
- Remaining RSUs: 5,095 restricted stock units beneficially owned directly following the transaction
- Vesting schedule: RSU Award vests over 3 years across multiple installment dates per the filing's explanation of responses
Cytek Biosciences Director Michael Holder Reports RSU Conversion on November 18, 2026
According to the Form 4 filed with the SEC on November 20, 2026, Michael Holder, a director of Cytek Biosciences, Inc. (NASDAQ:CTKB), reported the vesting of restricted stock units on November 18, 2026. The filing indicates a transaction code of M, reflecting the conversion of a derivative security into common stock. A total of 2,181 restricted stock units were converted, with each RSU representing, as the filing states, "a contingent right to receive one share of the Issuer's common stock."
Following the transaction, the filing reports that Holder directly holds 65,056 shares of Cytek Biosciences common stock. The derivative security table shows that 5,095 restricted stock units remain directly held by Holder after the reported transaction. The price of the derivative security is listed as $0 in the filing.
The filing's explanation of responses describes a multi-tranche vesting schedule for the RSU Award spanning 3 years. Per the filing, installments vest on specific dates including August 18, November 18, March 10, May 18, and August 18 of applicable years, with fractions of 2/36, 3/36, 4/36, 2/36, and 3/36 of the total shares underlying the award, respectively. The form was signed by Wenbin Jiang as attorney-in-fact on November 20, 2026.
What Was Disclosed
Cytek Biosciences director Michael Holder disclosed the vesting of 2,181 restricted stock units into common stock on November 18, 2026, leaving him with 65,056 shares of common stock and 5,095 remaining RSUs, all held directly.



Please wait processing your request...